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1. Introduction 
Antibiotics have shown a proven efficiency profile in therapy against some infectious agents 
for several decades. Nevertheless, a large-scale spreading of antibiotics in the environment, 
and emergence of resistant or even multi-resistant pathogenic bacterial strains has become a 
general concern promise to even further increase. Besides therapeutic applications, 
antibiotics are often used as a selection pressure to avoid bio-contamination in production 
processes such as fermentation. In this particular context the problem can show two distinct 
facets: the antibiotic molecule itself, seen as a contaminant product in a given biological and 
the antibiotic resistance gene used as a selection marker. 
The increasing regulatory requirements to which biological agents are subjected will 
hopefully have a great impact in the field of industrial protein expression and production. 
There is an expectation that in a near future, there may be “zero tolerance” towards 
antibiotic-based selection and production systems. Besides the antibiotic itself, the antibiotic 
resistance gene is a major subject of consideration. The complete absence of antibiotic-
resistance gene being the only way to ensure that propagation in the environment or 
transfer of resistance to pathogenic strains will not happen.  
In order to address these issues, different and complementary approaches can be applied. 
The first would be to design more stable host/vector couples allowing to set-up and 
conduct fermentation processes in complete absence of antibiotics. A more achieved strategy 
would be to substitute the antibiotic-based selection by an alternative mean such as the 
complementation of an essential gene product, not expressed by the host or sophisticated 
post-segregational killing mechanism. 
For specific therapeutic agents or fields of application such as DNA vaccination or gene 
therapy the presence of an antibiotic resistance gene in the vector backbone is seen as 
undesirable to health authorities. In that case the problem is the possibility of horizontal 
transfer of antibiotic resistance to circulating microbial population. 
2. Current selection methods 
2.1 Different antibiotic-based systems 
Most commercialized vectors use antibiotic-based selection markers. Ampicillin and 
kanamycin resistance genes are two widely used selection markers. 
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Ampicillin resistance gene, AmpR also known as blaTEM1, is derived from Salmonella 
paratyphi. It allows the synthesis of the beta-lactamase enzyme, which neutralizes antibiotics 
of the penicillin group, such as ampicillin. Surprisingly, ampicillin that is the most popular 
selection marker used in research laboratories is in fact a very inefficient selection mean in 
liquid cultures. The antibiotic-resistance gene product, -lactamase, efficiently secreted into 
the culture supernatant rapidly eliminates the antibiotic, even if used at high concentration. 
Chloramphenicol is more rarely used, or for some specific applications, for instance, large 
plasmid or cosmid DNA amplification. The spectra of activity of this antibiotic being 
variable between true bactericidal and bacteriostatic effect according to the gram character 
or nature of the bacterial strain considered (Rahal and Simberkoff 1979). 
Kanamycin resistance gene, KanR also know as ntpII (neomycin phosphotransferase II) was 
initially isolated from the transposon Tn5 that was present in the bacterium strain Escherichia 
coli K12. The gene encodes the aminoglycoside 3'-phosphotransferase enzyme, which 
inactivates by phosphorylation a range of aminoglycoside antibiotics such as neomycin and 
kanamycin. 
2.2 Advantages and drawbacks 
Even if antibiotic resistance gene are widely use for DNA production and recombinant 
protein expression in bacteria, regulatory agencies tend to restrict their use because of 
potential horizontal transfer to environmental bacteria. Indeed, due to several mechanisms 
of gene transfer between bacteria, a potential risk of antibiotic resistance spread exists. 
3. Potential concern  
3.1 Safety issue 
Antibiotic resistance genes are the most commonly used selectable markers for plasmid 
production (i.e. for vaccine or therapeutic DNA or for production of recombinant proteins as 
biotherapeutics).To date, kanamycin resistance gene is the most commonly used as 
selectable antibiotic marker. Ampicillin resistance gene is not acceptable due to concerns for 
patients which have reactivity to -lactam antibiotics. Tetracyclin resistance gene is toxic for 
E.coli (Williams et al., 2009) 
The major issue is the horizontal genetic transfer of antibiotic resistance gene to prokaryotic 
organisms present in the environment for biotherapeutic production or in commensal flora.  
3.2 Horizontal transfer 
Horizontal genetic transfer (HGT) is the passage of genetic elements between organisms 
(Tuller et al., 2011). This HGT is a major driving force in bacterial evolution by facilitating 
the diversity of bacteria. An essential element in HGT is to determine which factors 
influence the fixation of transferred genes. Some of these factors have already been 
identified (Tuller et al., 2011) and correspond to the advantage conferred by the transferred 
gene, the toxicity of its product, the ability of the transferred gene to be integrated into the 
host genome and to be stabilized, the number of interactions of the transferred gene product 
and the compatibility of codon usage between the transferred gene and the host. Tuller et 
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al., 2011, have shown a correlation between the number of horizontally transferred gene 
with different organisms and the similarity between their tRNA pools. Moreover, organisms 
present in a same ecological environment have similar tRNA pools. These two points 
increase the probability of integration and fixation of a HTG into a new host genome.  
Acquisition of antibiotic resistance is one element of this evolution by HTG. For example, 
Datta and Kontomichalou in 1965 have shown the importance of the penicillin resistance 
transfer across the Enterobacteriaceae. More recently, acquisition of the virulence factors that 
distinguish Salmonella from Escherichia coli has been shown as the result of HTG 
(Wiedenbeck & Cohan, 2011).  
Moreover, one element favoring HTG is the length of DNA and this is the case with plasmid 
harboring antibiotic resistance gene used in recombinant protein (biotherapeutic) 
expression.  
These elements are potential concerns that have to be taken into account in production of 
therapeutics or vaccine plasmid products and of biotherapeutics to restrict safety issues.  
4. Regulatory point of view 
A large number of guidance for industry, have been released by the FDA. Among these 
some are directly applied to the use of antibiotic resistance marker genes in different 
contexts such as transgenic plants at large or crops for animal feed. Here we have 
deliberately decided to restrict our focus on vaccines and biological therapeutics. 
The market of “biotherapeutics”, derived from recombinant DNA technologies, is entering 
an exponential growing phase. As much as 34 monoclonal antibodies have been, to date, 
approved by the FDA for various therapeutic applications. Besides antibodies, other 
products such as next generation recombinant vaccines and gene therapy constructs are 
progressively invading new therapeutic areas. As a result of growth in existing markets and 
the opening of new opportunities, the global demand is largely projected to further increase. 
A direct consequence is a progressive adaptation and strengthening of the existing 
regulation. A reasonable expectation is a move towards a “zero tolerance” for antibiotic 
based selection in production systems. 
4.1 North American & European regulation 
As soon as in July 1993, the FDA drafted some points to consider in the characterization of 
cell lines used to produce biological products. 
‘Penicillin or other beta lactam antibiotics should not be present in production cell cultures. 
Minimal concentrations of other antibiotics or inducing agents may be acceptable [21 CFR 
610.15(c)]. However, the presence of any antibiotic or inducing agent in the product is 
discouraged.’ 
The WHO technical report series N° 878: “Requirements for the use of animal cells as in vitro 
substrates for the production of biologicals”, published in 1998 goes exactly in the same 
direction. 
‘Penicillin or other -lactam antibiotics shall not be present in production cell cultures. 
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Minimal concentration of other antibiotics may be acceptable. However the presence of any 
antibiotic in a biological process or product is discouraged.’ 
Over the years the recommendation became more precise or specific to some categories of 
biological products such as DNA vaccines. The potential issue of allergic responses to some 
classes of antibiotics is evoked, the necessity to document the trace amount of antibiotics in 
the final product clearly seen as mandatory. And finally appears an interesting allusion to 
novel strategies to replace antibiotic-based selection. 
In December 1996 FDA issued a draft guidance entitled - Points to Consider on Plasmid 
DNA Vaccines for Preventive Infectious Disease Indications 
‘Antibiotic resistance is commonly employed as a selection marker. In considering the use of an 
antibiotic resistance marker, CBER is advising manufacturers against the use of penicillin or 
other beta-lactam antibiotics as these antibiotics can, in certain individuals, result in allergic 
reactions ranging in severity from skin rashes to immediate anaphylaxis. When an antibiotic 
resistance marker is required in a plasmid DNA vaccine construct, CBER advises the use of an 
antibiotic such as kanamycin or neomycin. These aminoglycoside antibiotics are not extensively 
used in the treatment of clinical infections due to their low activity spectrum, prevalence of 
kanamycin-resistant bacteria, and their problematic therapeutic index with toxicities including 
irreversible ototoxicity and nephrotoxicity. Specifications for the level of antibiotic present in the 
final container should be established and should consider the minimum level of antibiotic that 
will give an unintentional clinical effect. The use of alternative antibiotic resistance markers or 
the use of suppressor tRNA genes in a plasmid construct intended as plasmid DNA vaccine 
should be discussed with CBER prior to full scale development of a new vaccine product.’ 
Several updates (2006 and 2009) of this guidance are accessible on the web. 
The EMEA is perfectly in line with its North American counterpart, as a matter of example, 
a 2001 guidance indicates: 
 ‘lack of expression in mammalian cells should be verified due to regulatory concerns’ 
This comment is an illustration of the concern applied to the antibiotic-resistance gene itself. 
In a draft review, released from the FDA in November 2004, it is clearly specified that the use 
of beta-lactams should be avoided or at least very clearly documented in terms of safety for the 
patient. This recommendation, even if not prohibitive, appears as extremely dissuasive.  
Content and Review of Chemistry, Manufacturing and Control (CMC) Information for 
Human Gene Therapy Investigational New Drug Application (INDs) 
‘Because some patients may be sensitive to penicillin, we recommend that you, a sponsor, do not 
use beta-lactam antibiotics during the manufacturing of a therapeutic product for humans. If 
beta-lactam antibiotics are used, we recommend that you take and describe precautions to 
prevent hypersensitivity reactions.‘ 
In a recent release from the FDA (October 23, 2009) dedicated to Vaccines, Blood & Biologics, 
entitled: Common Ingredients in U.S. Licensed Vaccines: Why are antibiotics in some vaccines? 
‘Certain antibiotics may be used in some vaccine production to help prevent bacterial 
contamination during manufacturing. As a result, small amounts of antibiotics may be present 
in some vaccines. Because some antibiotics can cause severe allergic reactions in those children 
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allergic to them (like hives, swelling at the back of the throat, and low blood pressure), some 
parents are concerned that antibiotics contained in vaccines might be harmful. However, 
antibiotics most likely to cause severe allergic reactions (e.g., penicillins, cephalosporins and 
sulfa drugs) are not used in vaccine production, and therefore are not contained in vaccines.’ 
In the issue of july 7th 2011 of: Common Ingredients in U.S. Licensed Vaccines, some 
comments on antibiotics used in vaccine manufacturing processes are somewhat moderated. 
‘Examples of antibiotics used during vaccine manufacture include neomycin, polymyxin B, 
streptomycin and gentamicin. Some antibiotics used in vaccine production are present in the 
vaccine, either in very small amounts or they are undetectable. For example, antibiotics are used 
in some production methods for making inactivated influenza virus vaccines. They are used to 
reduce bacterial growth in eggs during processing steps, because eggs are not sterile products. 
The antibiotics that are used are reduced to very small or undetectable amounts during 
subsequent purification steps. The very small amounts of antibiotics contained in vaccines have 
not been clearly associated with severe allergic reactions.’ 
4.2 Conclusion and future rules 
According to the above mentioned information: 
- It is not yet prohibited but strongly advised to avoid or minimize the use of any kind of 
antibiotics in cell or bacterial culture, 
- If antibiotics are used, it is mandatory to minimize their amount and to control for the 
presence of traces in the final product, 
- The rationale for the use of antibiotics must be clearly documented in the CTD 
- Penicillin, more generally -lactams and streptomycin must not be used in reason of 
potential concerns with hyper reactivity of some patients to antibiotics of the -lactam 
family 
- Kanamycin and neomycin are the preferred choice and still tolerated. 
The use of antibiotic resistance markers is generally discouraged, and if used the in vivo 
effect needs to be evaluated. 
There are specific mentions for the nature of the gene encoding resistance to kanamycin, as 
reviewed by Williams et al., (2009). The gene neomycin phosphotransferase III [npt-III, aph 
(3′)-III] should be avoided, since it also confers resistance to amikacin, a reserve antibiotic 
(EMEA, 2008).  
As a final comment it is easy to anticipate, what might be the future requirements from 
health authorities: constructs have to be completely devoid of antibiotic resistance genes in 
their final structure, even if in use at early stages of construction. Alternative solutions 
would be available and validated soon. 
5. Alternatives to antibiotics in bio-production 
5.1 Vector stabilization 
One aspect to be considered during recombinant biopharmaceutical expression is the 
stability of the plasmid used. More than 20 years ago, several studies on natural plasmids 
have highlighted that some plasmids naturally display regions necessary for their stability. 
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Ogura & Higara,, 1983a, have shown that plasmid F, that exists only as one to two copies 
per chromosome and is stably inherited to daughter cells during cell growth, contains 
stabilization sequences. They did show that these sequences were independent from 
plasmid replication function. They first identify 3 regions essential for plasmid maintenance: 
SopA and SopB that acts in trans and SopC that acts in cis to stabilize the plasmid by probably 
interacting with cellular components. These authors also put in evidence that SopA, SopB 
and SopC were not sufficient for full stability of mini-F plasmid, and identified the ccd 
(control of cell death) region that seemed to control cell division when copy number 
carrying ccd segment decreases (Ogura & Higara, 1983b). The so-called ccd region is divided 
into two functional regions: ccdB, which product inhibits the host cell division and ccdA, 
which product is able to inhibit the ccdB function. Two years after, Jaffé et al., 1985, 
demonstrated that cell division is not immediately inhibited and that residual division could 
take place in the plasmid free-cells before finally being inhibited. Authors concluded that ccd 
region guarantees that plasmid carrying cells could grow preferentially in a population by 
killing plasmid free daughter cells, introducing the concept of post-segregational killing. 
Plasmid R1 has also been shown to contain a stabilization system (Gerdes et al., 1985). As for 
plamid F, the stabilization system is based on post segregational killing du to the parAB+ 
locus. This locus is composed of two genes Hok (Host killing) and Sok (suppression of 
killing). The translation of the Hok messenger, encoding a toxin lethal to the bacteria, is 
completely blocked by the anti-messenger Sok. In the absence of plasmid, Sok, which is less 
stable than Hok, is lost first, allowing the translation of the Hok mRNA and expression of 
the toxin lethal to the cell. 
Concerning plasmid maintenance, it has been shown that factors reducing mutlimerization 
of plasmid could increase plasmid stability (Summers & Sherratt, 1984). ColE1 plasmid 
contains a region, cer that seems to be necessary for a recombination event converting 
multimers to monomers, allowing the plasmid to be more stable. Multimer resolution is 
achieved through action of the XerCD site-specific recombinase at the cer site (see Figure 1). 
Cloning of the cer locus into various expression vectors has been extensively documented 
and the proof of principle largely established in high-cell density cultures. 
 
Fig. 1. Multimers resolution of high copy plasmids by XerC/D recombinase at cer locus. 
5.2 Genomic integration 
If mutation and deletion into E.coli genome are now widely used, it seems that genomic 
integration is not the preferred way to express a recombinant protein without antibiotic 
selection. However, some plasmid-free system have been described (see Figure 2). 
Xer C/D 
+ 
Rcd 
(regulator of cell division) 
Cer site 
The Cer locus 
Multimer resolution 
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Fig. 2. Establishment of a plasmid-free expression system, illustration adapted from 
Striedner et al., 2010. 
In 2009, a “plasmid-free T7-based E.coli expression system” has been developed by inserting 
a region of a pET plasmid into bacterial genome by λ Red recombination and P1 
transduction (Datsenko & Wanner, 2000, as cited in Striedner et al., 2010). The study 
compared protein expression between plasmid-based and plasmid-free expression system 
showing an improved protein production with chromosome-based system. This system also 
conferred a high stability and simple upstream processing as well as high flexibility in 
process design.(Striedner et al., 2010). 
More recently, Lemuth et al., 2011, reported the construction of the first plasmid-free E. coli 
strain that produces astaxanthin. This engineered E. coli strain harbors 5 heterologous 
biosynthetic genes from P. ananatis and one from N. punctiforme that are required for the 
formation of astaxanthin. Furthermore, a plasmid-free E.coli strain that accumulated 
astaxanthin as the exclusive carotenoid was engineered. This system presents many 
advantages compared to a plasmid-based strategy: a reduced metabolic burden, a better 
stability and obviously the absence of selection markers such as antibiotic resistance genes. 
5.3 Complementation of essential gene product and auxotrophy markers 
Essential gene complementation requires the engineering of a bacterial strain lacking an 
essential gene. The activity of the lacking gene product can be complemented by the culture 
medium or by transforming the bacteria with a plasmid having this gene as selection marker 
(see Figure 3).  
Several antibiotic-free selection systems are based on gene complementation. One of the first 
systems was based on dapD gene (Degryse, 1991). The dapD gene, which has a role in the 
lysine biosynthetic pathway as well as cell wall assembly, has been selected as a preferred 
candidate by several authors, knowing that mutations in the DAP pathway are lethal. The 
limitations, in that case, are the intrinsic difficulty in construction of a dapD mutant strain 
and the dependence towards defined culture media composition. 
Based on the same gene, a more elaborated strategy called “operator repressor titration” 
emerged in 2001. In this system, dapD gene is engineered in order to be under the control of 
lac Operon. When not supplemented with IPTG or DAP, dapD gene is not expressed 
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Fig. 3. Antibiotic-free selection system based on essential gene complementation. 
inducing bacterial death. When the strain is transformed by a lac operator containing multi 
copy plasmid, the operator competitively titrates the Lac I repressor and allows the 
expression of dapD from the lac promoter allowing bacterial growth. (Cranenburgh et al., 
2001 & 2004) 
Other essential genes have been selected for the same purpose, such as infA, coding for 
translation initiation factor 1 (IF1), an essential protein for cell viability. In 2004, Hägg et al. 
generated a strain in which the infA gene has been deleted by a plasmid-based gene 
replacement method. They used a plasmid encoding a functional IF1 as selection marker and 
show that the system is tightly regulated and that no cross feeding is observed since initiation 
factors released into the media from lysed cells are not absorbed by plasmid-free cells. 
The fabl essential gene has been used in an original way because of its property to reduce the 
E.coli susceptibility to triclosan when overexpressed. In this system, only plasmid containing 
cells overexpress fabl gene and can grow in presence of triclosan. Even if triclosan is a 
biocide, it is considered as non-antibiotic and regulatory agencies approve the use of 
triclosan for clinical use (Goh & Good, 2008). 
More recently, Dong et al., 2010, developed a novel antibiotic-free selection system based on 
complementation of host auxotrophy in the NAD synthesis pathway. NAD can be de novo 
synthesized from tryptophan and aspartate with the quinolinic acid phosphoribosyltransferase 
(QAPRTase) or synthesized using the salvage pathway according to different substrates such 
as nicotinamide. Authors constructed a bacterial strain depleted for QAPRTase gene that can 
only grow if the NAD synthesis pathway is complemented by addition of salvage pathway 
substrate or QAPRTase gene present on a plasmid. The results obtained with this novel 
selection system show that the QAPRTase seletion marker does not represent a metabolic 
burden for bacterial growth and the stability of all plasmid harboring this system were 100% 
in the ΔQAPRTase strain even after 6 days of continuous growth. In this study, reserchers 
went further by complementing for the first time in an antibiotic-free selection system a 
bacterial strain by a mammalian QAPRTase gene with success. 
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A strain is auxotrophic for one amino-acid if it carries a genetic mutation that renders it 
unable to synthesize the amino-acid. Such a strain will be able to grow only if the amino-
acid is present in the environment or if the functional gene product is expressed from a 
plasmid. Amino-acid auxotrophy markers had been investigated as novel antibiotic-free 
selection markers. 
In 2001, Fiedler & Skerra developed expression vectors containing the proAB gene, in order to 
complement their proline-auxotrophic K12 strain. Their aim was not to develop an antibiotic-
free selection system but to use their strain to obtain a better expression of recombinant 
antibody Fab fragment. For this reason, the plasmid-mediated complementation is used 
simultaneously with beta-lactamase selection to completely abolish plasmid loss during high 
scale fermentation. 
In 2008, Vidal et al. described a plasmid selection system, devoid of antibiotic resistance 
gene and based on glycine auxotrophy. Researchers generated an E.coli strain that contains a 
deletion in the glyA gene, which encode for serine hydroxymethyl transferase, an enzyme 
involved in glycine biosynthesis pathway in E.coli. This strain can grow fast on a defined 
media only if glycine is added to the culture medium or if the bacteria harbor a plasmid 
expressing a functional glyA gene. They show comparable amount of recombinant protein 
with their system compared to a classical beta-lactamase selection system. 
5.4 RNA-based antibiotic-free selection systems 
Several antibiotic-free selection strategies are based on RNA, using antisense or anti-
messenger properties or using suppressor tRNA. 
The principle of down regulating an essential gene upon plasmid loss has been exploited in 
a very original way for the design of new vectors for gene therapy (Mairhofer et al., 2008). 
The expression of the essential gene murA encoding an enzyme essential for the biosynthesis 
of cell wall is under control of the Tet repressor, TetR expression is inhibited by an RNA-
RNA antisense interaction with RNAI derived from plasmid origin of replication ColE1 (see 
Figure 4A). The major advantage of this system is that no additional sequence is required on 
the plasmid. (Pfaffenzeller et al., 2006; see figure 4B)  
In a recent paper, RNA based selectable marker, not restricted to ColE1 containing vectors is 
described (Luke et al., 2009). Briefly, a counter-selectable marker (sacB) levansucrase from 
Bacillus subtilis, under control of the RNA-IN promoter is integrated into the bacterial 
chromosome induces cell death in presence of sucrose. Plasmid maintenance is ensured by 
the presence of the plasmid-borne regulator RNA-OUT anti-messenger acting as a down 
regulator of the expression of levansucrase (see Figure 4C). 
Another vector system so-called pCOR, based on the complementation of an amber 
mutation using a suppressor tRNA, and conditional origin of replication has also been 
established (Soubrier et al., 1999). The original feature of the model is that an additional 
degree of refinement was introduced, since the dependence created between the host and 
the vector has become bilateral (see Figure 4D). 
Nevertheless, the requirement for a minimal medium for culture means these systems are 
more likely to be used for DNA production rather than recombinant protein over expression. 
www.intechopen.com
 
Antibiotic Resistant Bacteria – A Continuous Challenge in the New Millennium 
 
540 
 
Fig. 4. RNA-based antibiotic-free systems. Illustration adapted from Pfaffenzeller et al., 2006; 
Luke et al., 2009 & Soubrier et al., 1999. 
5.5 Post-segregational killing 
Post-segregational killing is a mechanism by which plasmids are stably maintained by 
expressing a gene product that would be toxic to cells becoming plasmid-free upon division 
(see Figure 5). This mechanism, discovered on natural plasmid, has been used as selection 
system devoid of antibiotic. 
One of these systems, based on ccdA/ccdB genes has been proposed by Szpirer & 
Milinkovitch, 2005, and is commercialized by the Delphigenetics Company. ccdB gene is 
inserted into the bacterial genome of the E. coli strain BL21 (DE3) and encodes a stable 
protein (100 aa), binding gyrase, essential for cell division. Upon binding gyrase, the ccdB 
gene product impairs DNA replication and induces cell death. ccdA gene, plasmid-born, 
encodes an instable protein (90 aa) under control of the mob promoter, acting as a natural 
inhibitor of ccdB. It has been shown that after 20 generations on a non-selective medium 
100% of the bacteria still contain the plasmid. Two hours after induction, the plasmid is still 
present into all bacteria, which is not the case with a standard pET/BL21DE3 system. 
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Fig. 5. Antibiotic-free selection system based on Toxin/antitoxin post-segragational killing. 
Illustration adapted from Szpirer & Milinkovitch, 2005. 
To go further, Peubez et al. proposed in 2010 a system combining the ccdA/ccdB selection 
marker to the cer fragment to increase plasmid stability among long-term fermentation. 
Different toxin/antitoxin (TA) systems have been described and could allow the generation 
of novel antibiotic-free systems. In order to detect putative TA systems, Milinkovitch's team 
had developed an algorithm based on predefined similarities and TA-specific structural 
constraints (Guglielmini et al., 2008). 
Interestingly, this TA-based antibiotic-free selection system is starting to be adapted to 
mammalian cells selection. The toxin Kid (Killing determinant) and its antidote Kis (killing 
suppressor) have been used to control cell proliferation during expression of a recombinant 
protein in CHO-K1 cells (Nehlsen et al., 2010). If antibiotics are still used in this study, 
authors show that the TA strategy can significantly increase the recombinant protein 
expression level and could be a benefit for “difficult” to produce proteins. 
6. Additional benefits 
6.1 Recombinant protein production 
In many cases, especially for “difficult proteins” the yield of protein production has proven 
to be higher with antibiotic-free system compared to a conventional one. The presence of an 
antibiotic resistance gene can indirectly reduce the amount of expressed protein, since even 
in absence of selection pressure the gene would be transcribed and account for an additional 
stress for the host during the fermentation process. However, even if the yield of protein is 
not superior to a conventional system, the antibiotic-free systems remain interesting due to 
their biosafety. 
6.1.1 Plasmid stabilisation cer locus 
Most commonly used multicopy plasmids are unstable and are lost during culture. Plasmid 
stabilization and increased maintenance during a fermentation process can be considered as 
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a first step towards antibiotic starvation. Genetic elements allowing plasmid maintenance 
during cell division and limiting the probability of plasmid loss over generations should be 
considered. 
To stabilize the plasmid, the well–studied mechanism of site specific recombination of E.Coli 
plasmid ColE1 can be used. The 380 bp Cer fragment was inserted into the plasmid carrying 
the gene of interest and the multimers are resolved to monomers by the Xer recombinase. 
(Described in 5.1, see Figure 1) 
Tables 1 and 2 show the contribution of the cer fragment in increasing the plasmid 
maintenance over time is clearly established. The plasmid loss is dependant on the antigen 
expressed. 
79%3%23h
75%20%6h
100%25%4h
100%97%2h( IPTG added)
With cerPlasmid without cerCulture time
 
Table 1. Example of Helicobacter pylori AlpA protein produced in erlen flask in absence of 
Kanamycin. 
 
Table 2. Example of Helicobacter pylori Urease produced in erlen flask in absence of 
kanamycin. 
6.1.2 ccdA/ccdB 
The combination of different genetic elements can allow an increased stability and 
antibiotic-free selection. In this case, the kanamycin resistant gene present on the vector 
backbone was eliminated by a restriction enzyme digestion and self–relegation.  
The selection system based on the couple poison (gene ccdB)/antidote:(gene ccdA), proposed 
by Szpirer & Milinkovitch, 2005, combined with the stabilizing element, the cer locus, was 
tested to express different recombinant proteins. 
- the poison gene (ccdB), inserted into the bacterial genome, encodes a stable protein (100 
aa), which is an inhibitor of the DNA replication capable to bind to the gyrase ( an 
essential protein for cell division). This interaction induces the cell death.  
9%0%25h
50%1%5h
100%67%3h
IPTG addition2h
100%87%1h
With cerPlasmid without cerCulture time
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- the antidote gene (ccdA), localized on the plasmid under the control of a constitutive 
promoter, encodes for a small unstable protein (90aa) which neutralizes the effect of 
ccdB protein action. 
E.coli BL21/PM1816 
(existing system)
E.coli SE1/pSP1 
(antibiotic-free)
0h0h 1h1h 2h2h 3h3h 19h 18h
603337273110818 143 289 376 280
mg rEPA per 
liter of culture
Induction Time 
at OD=25
 
Fig. 6. Protein production evaluation in 1 liter fermenter. 
Figure 6 shows a comparison of expression of the same protein with the kanamycin resistant 
gene (E. coli BL21/pM1816) and the antibiotic-free system (E. coli SE1/pSP1) without the 
kanamycin resistant gene and with the ccdA gene. Both have the cer element. Upon 
induction, the behavior of both systems is comparable but a clear increase in protein 
production is observed with the antibiotic-free system at the end of fermentation. 
6.1.3 Antibiotic resistance gene elimination 
Antibiotic-based selection, convenient for cloning steps, must be removed for production. 
Even if antibiotic selection pressure is not used during the fermentation process, removal of 
this antibiotic resistance marker is of major importance to prevent horizontal transfer in the 
environment. This is particularly true for vectors to be used in gene therapy or DNA 
vaccination protocols 
ccdA 5’ Kana ccdA 3’ Ka   na 
na 
Ka ccdA 5’ 
ccdA 3’ 
Full size ccdA 
Bacterial tranformation 
with linear plasmid 
Homologous recombination 
Digestion 
 
Fig. 7. Homologous recombination process allowing assembly of a functional ccdA encoding 
gene. 
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In order to overcome the problem of positive pressure of selection, a new apporach has been 
developed ensuring the elimination of the antibiotic-resistance gene through homologous 
recombination. In this model the ccdA locus is split into 2 parts, containing a common 
sequence, and cloned at the 5’ and 3’ regions flanking the antibiotic resistance gene (figure 
7). After digestion at a unique restriction site located inside the antibiotic selection marker 
and transformation of ccdB expressing cells with linear DNA, a fully functional ccdA would 
assemble through homologous recombination. Only bacteria containing a recombinant 
plasmid with a functional ccdA can grow upon transformation. 
6.1.4 Summary of different antibiotic-free systems 
System 
developed 
Mode of action 
Protein 
expressed 
Comments/
potential 
drawbacks
Ref article 
Plasmid-free 
system 
Chromosome 
based expression 
system 
GFP
Human 
superoxide 
dismutase(SOD)
Modified E coli 
strain, required 
Striedner et al., 
2010 
Fabl-triclosan 
Endogenous 
essential gene 
None 
Chemical Biocid 
utilisation 
Goh & Good, 
2008 
E. coli strain 
ΔQAPRTase 
gene 
Complementation EGFP 
Modified E coli 
strain, required 
Dong et al., 2010 
Pro BA Complementation Fab fragment 
Modified E coli
strain, required 
Presence of 
antibiotic 
Fiedler & Skerra, 
2001 
 
E coli strain 
ΔglyA 
Glycine 
auxotrophy 
RhuA 
Modified E coli 
strain, required. 
Comparable to the 
conventional system
Vidal et al., 2008 
RNA/RNA 
interference 
RNA/RNA 
interaction 
EGFP 
Modified E coli 
strain, required 
Pfaffenzeller et 
al., 2006 
RNA out 
RNA/RNA 
interaction 
EGFP 
HA vaccine 
candidate
 Luke et al., 2009 
pCOr 
Complementation 
of amber mutation
tRNA suppressor
Luciferase 
Modified E coli 
strain, and 
minimum medium 
required 
Soubrier et al., 
1999 
ccdA/ccdB Toxin/antitoxin 
AlpA/rEPA 
vaccine 
candidates
Modified E coli 
strain required 
Peubez et al., 
2010 
Kid/Kis Toxin/antitoxin EGFP 
Presence of 
antibiotic
Nehlsen et al., 
2010 
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6.2 DNA immunization and gene therapy 
Requirement can also be variable according to the nature of the therapeutic product, the 
presence of an antibiotic resistance gene, tolerated on a vector expressing a recombinant 
biopharmaceutical, will be totally undesirable on a gene therapy plasmid. 
Among systems described in paragraph 5, some have been developed especially for DNA 
vaccine production such as pCOR (Soubrier et al., 1989), RNA/RNA interference 
(Pfaffenzeller et al., 2006) and RNA out (Luke et al., 2009). 
To go further, Carnes et al., 2009, have proposed a combination of antibiotic-free selection 
system and an autolytic E.coli strain to improve both upstream and downstream processes. 
The antibiotic-free selection is based on RNA selectable marker described by Luke et al., 
2009 and the autolytic plasmid DNA extraction method uses integrated bacteriophage 
endolysin gene (λR), encoding a peptidoglycan hydrolase (lysozyme) enzyme to 
permeabilize the bacterial cell wall, and to selectively extract the plasmid DNA from the 
cells in an acetate buffer. Authors found that their autolytic strain allowed efficient plasmid 
DNA recovery, similar to alkaline lysis plasmid DNA purification. 
7. Conclusion and perspectives 
Antibiotic-free selection is a general and ultimate goal that can be reached by the 
implementation of various and combined approaches. An increasing knowledge of bacterial 
physiology will give access to comprehensive information on essential genes or pathways 
that would be an unlimited source of inspiration for the design of novel selection means.  
The major driver for the definition of antibiotic-free systems is an anticipation of fulfilling 
future recommendations from health authorities to overcome safety concerns. It is easy to 
imagine that, upon availability and functional validation, these alternative selection means 
will progressively gain the status of “preferred”, “strongly recommended” and finally 
“mandatory”. 
In addition to their safety profile, some antibiotic-free systems can give access to unexpected 
properties such as a marked increase in recombinant protein production or plasmid 
recovery.  
The complete elimination of any antibiotic resistance gene is, for different reasons, of critical 
importance for recombinant protein production, DNA immunization and gene therapy 
vectors.  
It is likely to think that upon validation at industrial scale, antibiotic-free selection might be 
an added value for biotherapeutics in terms of safety profile of the product and become an 
important element of the marketing strategy as well. A direct consequence would be the 
emergence of a new “gold standard”. 
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